May 17, 2006 – Novartis released information showing that Rasilez reduces blood pressure over a 24-hour period without causing undue side effects; Shire announced the FDA will take an extra three months to rule on Elaprase, a treatment for Hunter syndrome; Amicus Therapeutics filed to raise up to $86.25 million in an IPO; Teva won FDA approval for Azilect, a therapy for Parkinson’s disease; Genzyme has made available two new tests for leukemia; and Medtronic won FDA approval for cardiac devices that communicate wirelessly with physicians. The Centient Biotech 200™ fell 56 points to 3635.75, a loss of 1.52%. More details...
